Takeda plans to submit data from the study for later presentation and initiate a Phase IIb trial of the drug, TAK-062, in celiac disease patients. In October, it in-licensed another celiac disease drug, COUR Pharmaceuticals' CNP-101/TAK-101.
Washington University spin-out PvP Biologics has bypassed traditional seed financing, jumping straight into a development agreement with Takeda Pharmaceuticals to further its investigational therapy for celiac disease.
There are a number of criteria for selecting the best autism therapy centers. Parents choosing a facility or professionals seeking to improve their offerings should consider certain standards to ensure the right fit.